세계의 항생제 시장 : 작용기전, 약제 클래스별, 스펙트럼, 카테고리, 용도, 투여 경로, 유통 채널별 예측(2025-2030년)

The Antibiotics Market was valued at USD 43.08 billion in 2023, expected to reach USD 45.74 billion in 2024, and is projected to grow at a CAGR of 6.81%, to USD 68.35 billion by 2030.

The antibiotics market encompasses the investigation of drugs that combat bacterial infections by either killing bacteria or hindering their growth. Its scope includes various classes such as beta-lactams, tetracyclines, macrolides, aminoglycosides, and others, spanning applications in human health, veterinary use, and agricultural purposes. The necessity for antibiotics arises from their crucial role in treating bacterial diseases, preventing the spread of infections, and safeguarding public health, notably essential in surgeries, cancer treatment, and as prophylaxis during pandemics. End-use scopes range widely from hospitals, clinics, and home healthcare settings to animal husbandry, where antibiotics enhance productivity and safeguard livestock health. Growth is propelled by increasing bacterial infections, rising demand in emerging markets due to improved healthcare, and innovations in antibiotic formulations combating resistant strains. Potential opportunities lie in the development of narrow-spectrum antibiotics, leveraging biotechnology for novel antimicrobial agents, and investing in rapid diagnostic technologies that tailor antibiotic use more precisely. However, challenges such as antibiotic resistance, regulatory hurdles, and the decline in antibiotic production profitability impede market expansion. Limitations include the overuse and misuse of antibiotics, leading to the emergence of multi-drug-resistant organisms, and debates surrounding the use of antibiotics in livestock contributing to resistance. For innovation, focus on research in antimicrobial peptides, exploring synergies with immunotherapy, and leveraging AI for drug discovery can steer industry growth. Viable areas for innovation include developing resistance-breaking molecules and next-generation sequencing technology to improve precision in antibiotic deployment, suggesting a market poised for technologically driven transformation. Thus, while the antibiotics market encounters numerous challenges, strategic focus on innovation and regulatory collaboration can open pathways for sustainable growth and development in this critical healthcare sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibiotics Market

The Antibiotics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of infectious and chronic diseases worldwide
  • Inclination toward early diagnosis and treatment of diseases
  • Rise in the number of clinical trials for the development of novel antibiotics trials
• Market Restraints
  • Concerns associated with antibiotics resistance
• Market Opportunities
  • Advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections
  • Growing in R&D and investments for the development of new drugs
• Market Challenges
  • Side effects caused by the usage of antibiotic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antibiotics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibiotics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibiotics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibiotics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibiotics Market

A detailed market share analysis in the Antibiotics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibiotics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibiotics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibiotics Market

A strategic analysis of the Antibiotics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibiotics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals LLC, Astellas Pharma, Inc., Bausch Health Companies, Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Healthcare Ltd., Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Glenmark Pharmaceuticals Limited, Hetero Healthcare, Johnson & Johnson Services, Inc., KYORIN Holdings, Inc., Lupin Limited, Melinta Therapeutics, Inc., Merck & Co., Inc., MerLion Pharmaceuticals GmbH, Mylan N.V. by Viatris, Novartis International AG, Pfizer Inc., Sanofi S.A., Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibiotics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Action Mechanism, market is studied across Cell Wall Synthesis Inhibitors, DNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Protein Synthesis Inhibitors, and RNA Synthesis Inhibitors.
• Based on Drug Class, market is studied across Aminoglycosides, Carbapenem, Cephalosporin, Fluoroquinolone, Macrolides, Penicillin, and Sulfonamides.
• Based on Spectrum, market is studied across Broad-spectrum Antibiotics and Narrow-spectrum Antibiotics.
• Based on Category, market is studied across Branded Antibiotics and Generic Antibiotics.
• Based on Application, market is studied across Ear Infection, Gastrointestinal Infections, Respiratory Infections, Septicemia, Skin Infections, and Urinary Tract Infections.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of infectious and chronic diseases worldwide
    • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    • 5.1.1.3. Rise in the number of clinical trials for the development of novel antibiotics

trials

• 5.1.2. Restraints
  • 5.1.2.1. Concerns associated with antibiotics resistance
• 5.1.3. Opportunities
  • 5.1.3.1. Advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections
  • 5.1.3.2. Growing in R&D and investments for the development of new drugs
• 5.1.4. Challenges
  • 5.1.4.1. Side effects caused by the usage of antibiotic drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibiotics Market, by Action Mechanism

• 6.1. Introduction
• 6.2. Cell Wall Synthesis Inhibitors
• 6.3. DNA Synthesis Inhibitors
• 6.4. Mycolic Acid Inhibitors
• 6.5. Protein Synthesis Inhibitors
• 6.6. RNA Synthesis Inhibitors

7. Antibiotics Market, by Drug Class

• 7.1. Introduction
• 7.2. Aminoglycosides
• 7.3. Carbapenem
• 7.4. Cephalosporin
• 7.5. Fluoroquinolone
• 7.6. Macrolides
• 7.7. Penicillin
• 7.8. Sulfonamides

8. Antibiotics Market, by Spectrum

• 8.1. Introduction
• 8.2. Broad-spectrum Antibiotics
• 8.3. Narrow-spectrum Antibiotics

9. Antibiotics Market, by Category

• 9.1. Introduction
• 9.2. Branded Antibiotics
• 9.3. Generic Antibiotics

10. Antibiotics Market, by Application

• 10.1. Introduction
• 10.2. Ear Infection
• 10.3. Gastrointestinal Infections
• 10.4. Respiratory Infections
• 10.5. Septicemia
• 10.6. Skin Infections
• 10.7. Urinary Tract Infections

11. Antibiotics Market, by Route of Administration

• 11.1. Introduction
• 11.2. Oral
• 11.3. Parenteral

12. Antibiotics Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Americas Antibiotics Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Antibiotics Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Antibiotics Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Amneal Pharmaceuticals LLC
• 3. Astellas Pharma, Inc.
• 4. Bausch Health Companies, Inc.
• 5. Bayer AG
• 6. Bristol-Myers Squibb Company
• 7. Cadila Healthcare Ltd.
• 8. Dr. Reddy's Laboratories
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche AG
• 11. Glenmark Pharmaceuticals Limited
• 12. Hetero Healthcare
• 13. Johnson & Johnson Services, Inc.
• 14. KYORIN Holdings, Inc.
• 15. Lupin Limited
• 16. Melinta Therapeutics, Inc.
• 17. Merck & Co., Inc.
• 18. MerLion Pharmaceuticals GmbH
• 19. Mylan N.V. by Viatris
• 20. Novartis International AG
• 21. Pfizer Inc.
• 22. Sanofi S.A.
• 23. Shionogi & Co., Ltd.
• 24. Sun Pharmaceutical Industries Limited
• 25. Teva Pharmaceutical Industries Ltd.